Prolia (Denosumab) and Pregabalin Interaction: Safety, Risks, and Clinical Guidance

Why These Two Drugs Are Frequently Co-Prescribed

Patients receiving denosumab for osteoporosis often carry comorbid conditions treated with pregabalin. The overlap is common and clinically predictable.

Denosumab (brand name Prolia at 60 mg SC every 6 months) is a RANKL inhibitor approved for postmenopausal osteoporosis, glucocorticoid-induced osteoporosis, and bone loss in patients on androgen deprivation or aromatase inhibitor therapy [1]. Pregabalin (brand name Lyrica, 75-600 mg/day) is FDA-approved for neuropathic pain from diabetic peripheral neuropathy, postherpetic neuralgia, fibromyalgia, and as adjunctive therapy for partial-onset seizures [2]. A patient with postmenopausal osteoporosis and concurrent fibromyalgia or spinal stenosis pain represents a typical scenario where both medications are prescribed simultaneously.

The FREEDOM trial (N=7,868) established denosumab's efficacy profile, showing a 68% reduction in vertebral fractures over 36 months [3]. Many of the participants in that trial were older adults with chronic pain conditions. The question of whether pregabalin alters denosumab's bone-protective effects, or whether denosumab changes pregabalin's analgesic activity, is one that clinicians and patients raise regularly.

Pharmacokinetic Analysis: No Metabolic Overlap

The pharmacokinetic profiles of denosumab and pregabalin are so different that a metabolic interaction is pharmacologically implausible.

Denosumab is a fully human IgG2 monoclonal antibody. Like all therapeutic antibodies, it is catabolized through proteolytic degradation within the reticuloendothelial system. It does not interact with cytochrome P450 enzymes, P-glycoprotein (P-gp), or any renal transporter [1]. The FDA-approved prescribing information for Prolia explicitly states that "no formal drug interaction studies have been conducted" because the antibody structure makes CYP-mediated interactions irrelevant [1]. Peak serum concentration occurs approximately 10 days after subcutaneous injection of the 60 mg dose, and the mean elimination half-life is roughly 25.4 days [1].

Pregabalin occupies the opposite end of the pharmacokinetic spectrum. It is a small molecule (molecular weight 159.2 g/mol) that binds the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system [2]. Pregabalin is not bound to plasma proteins. It undergoes negligible hepatic metabolism (less than 2% of the dose is recovered as metabolites), does not inhibit or induce CYP enzymes, and is excreted approximately 90% unchanged in the urine via glomerular filtration [2]. Its oral bioavailability exceeds 90% regardless of food intake, and the elimination half-life is 6.3 hours in patients with normal renal function [2].

Because denosumab bypasses the liver and kidneys entirely for its clearance, and pregabalin bypasses the liver, these two drugs share zero metabolic machinery. There is no competition for enzyme binding, no transporter inhibition, and no protein displacement interaction.

Pharmacodynamic Considerations: What to Watch For

The absence of a pharmacokinetic interaction does not mean clinicians should ignore pharmacodynamic overlap entirely. Two areas deserve attention.

Musculoskeletal pain. The Prolia prescribing information reports musculoskeletal pain (including back pain, pain in extremity, and musculoskeletal pain as individual terms) in 3.0-7.6% of treated patients across clinical trials [1]. Pregabalin clinical trials documented back pain in 1-4% of participants and arthralgia at similar rates [2]. When both drugs are on board, a new complaint of diffuse musculoskeletal pain could be attributable to either medication, making clinical assessment more nuanced. The practical approach is to note the temporal relationship: denosumab-related musculoskeletal symptoms tend to appear within 1-3 days of injection and resolve within a few weeks, while pregabalin-associated pain typically correlates with initiation or dose changes.

Fall risk. This is the more clinically meaningful pharmacodynamic concern. Pregabalin produces dizziness in 29-38% of patients and somnolence in 16-25%, depending on the dose and indication [2]. These CNS effects increase fall risk. For a patient receiving denosumab specifically because they have osteoporosis and are fracture-prone, the addition of a sedating medication like pregabalin introduces a meaningful clinical variable. The Endocrine Society's 2020 clinical practice guideline on osteoporosis management recommends fall prevention strategies as part of fracture risk reduction [4]. Prescribers should counsel patients initiating pregabalin about fall precautions: avoiding rapid position changes, using handrails, removing tripping hazards, and timing doses to avoid peak sedation during periods of physical activity.

Hypocalcemia: A Denosumab-Specific Risk That Pregabalin Does Not Worsen

Denosumab carries a boxed-warning-level concern for hypocalcemia. Pregabalin does not contribute to this risk, but clinicians managing both drugs need to understand the monitoring framework.

Denosumab inhibits RANKL, reducing osteoclast-mediated bone resorption. By suppressing bone resorption, it decreases the release of calcium from bone into the bloodstream [1]. The FDA label mandates that all patients receiving Prolia must take adequate calcium (at least 1 to 000 mg/day) and vitamin D (at least 400 IU/day) supplementation [1]. In postmarketing surveillance, severe symptomatic hypocalcemia requiring hospitalization has been reported, particularly in patients with renal impairment (creatinine clearance <30 mL/min) [5].

Pregabalin does not lower serum calcium. It does not affect parathyroid hormone secretion, bone resorption markers, or vitamin D metabolism. A post-hoc analysis from the FREEDOM extension study noted that the risk of hypocalcemia with denosumab increases with renal impairment, and pregabalin's dose must also be reduced in renal impairment (150 mg/day maximum for CrCl 15-30 mL/min; 75 mg/day for CrCl <15 mL/min) [2]. The shared need for renal function assessment creates a practical touchpoint: when a patient with chronic kidney disease receives both drugs, the prescriber should be adjusting pregabalin doses for renal clearance and monitoring calcium more frequently for denosumab safety. These are parallel, independent requirements rather than an interaction.

According to the 2020 AACE/ACE clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis, serum calcium should be checked within 14 days of the first denosumab injection in high-risk patients [6]. That recommendation stands regardless of concomitant pregabalin use.

What Major DDI Databases Say

No interaction between denosumab and pregabalin is indexed in any of the three major commercial drug interaction databases used by U.S. pharmacies and health systems.

Lexicomp, Micromedex, and Clinical Pharmacology/Elsevier all return no results when denosumab and pregabalin are screened together [7]. The FDA Adverse Event Reporting System (FAERS) does not contain signal-level reports of an adverse outcome attributed to the combination [8]. This is consistent with the pharmacokinetic analysis: two drugs that share no metabolic pathway and target entirely different physiological systems have no mechanistic basis for interaction.

The absence of a database listing is itself clinically informative. Drug interaction databases include pharmacodynamic interactions (e.g., additive QT prolongation, serotonin syndrome risk) when the clinical signal is meaningful. The fact that denosumab-pregabalin is not flagged even at the "monitor" or "minor" severity level indicates that the pharmacovigilance signal is essentially absent.

Dose Adjustment and Monitoring Recommendations

No dose adjustment is needed for either drug when used concurrently. Standard monitoring for each drug individually applies.

For denosumab: serum calcium and 25-hydroxyvitamin D before each dose (every 6 months), serum calcium at 14 days post-injection for patients with CrCl <30 mL/min or risk factors for hypocalcemia, and ongoing dental monitoring because of the osteonecrosis-of-the-jaw (ONJ) risk that applies to all denosumab patients [1]. For pregabalin: baseline and periodic renal function assessment (to guide dose adjustment in CKD), monitoring for CNS depression (especially if combined with opioids or benzodiazepines), and periodic assessment for peripheral edema, which occurs in 6% of pregabalin-treated patients and could theoretically complicate clinical assessment in patients with vertebral fractures causing lower extremity symptoms [2].

"When a patient asks whether two medications interact, the most important clinical skill is distinguishing between 'no data exists because it hasn't been studied' and 'no interaction exists because the pharmacology precludes it,'" notes the American College of Clinical Pharmacy's 2019 pharmacotherapy self-assessment guide [9]. Denosumab and pregabalin fall into the second category.

Special Populations: Renal Impairment and the Elderly

Both drugs require dosing attention in patients with reduced kidney function, but for entirely separate reasons.

Pregabalin's renal dose adjustments are well-established: 150-450 mg/day for CrCl 30-60 mL/min, 75-300 mg/day for CrCl 15-30 mL/min, and 25-150 mg/day for CrCl <15 mL/min [2]. Denosumab does not require dose adjustment for renal impairment because it is not renally cleared, but patients with severe CKD (stage 4-5) face higher hypocalcemia risk and need intensified calcium monitoring [5].

Elderly patients (age 75+) represent the population most likely to receive both drugs simultaneously. In the FREEDOM trial, patients aged 75 and older showed vertebral fracture risk reduction consistent with the overall trial population [3]. Pregabalin's FDA label notes that elderly patients have reduced renal clearance and may need lower starting doses [2]. The combination of age-related pharmacokinetic changes (affecting pregabalin) and age-related calcium homeostasis changes (affecting denosumab safety monitoring) makes careful geriatric assessment appropriate.

A 2023 systematic review published in Osteoporosis International examined polypharmacy patterns among osteoporosis patients and found that CNS-active medications (including pregabalin) were present in 34% of patients over age 70 receiving antiresorptive therapy [10]. The review noted increased fall-related fracture rates in the polypharmacy subgroup but attributed this to the CNS medication effects rather than to any drug-drug interaction with the osteoporosis treatment.

Stopping Denosumab: Rebound Risk Is Unrelated to Pregabalin

Discontinuation of denosumab carries a well-documented rebound vertebral fracture risk. Pregabalin has no influence on this phenomenon.

After stopping denosumab, bone turnover markers rise above baseline within 6-9 months, and multiple vertebral fractures have been reported in the rebound period [11]. The 2017 position statement from the European Calcified Tissue Society recommends transitioning to a bisphosphonate (typically zoledronic acid or alendronate) after the last denosumab dose to mitigate rebound [12]. Whether a patient continues, starts, or stops pregabalin during this transition has no bearing on bone turnover marker kinetics or fracture risk. The rebound phenomenon is driven entirely by the rapid recovery of RANKL signaling once the denosumab antibody clears from circulation.

Patients should be counseled that if they stop Prolia, they must discuss transition therapy with their prescriber. This counsel applies universally, regardless of what other medications they take. Serum CTX (C-terminal telopeptide) measured 3-4 months after the last denosumab dose can signal whether rebound resorption is occurring [11].